1D09C3, an mAb specific for MHC-II
Date
2008
Authors
Zola, H.
Beare, A.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Current Opinion in Molecular Therapeutics, 2008; 10(1):68-74
Statement of Responsibility
H Zola and A Beare
Conference Name
Abstract
GPC Biotech AG is developing 1D09C3, an anti-MHC class II (HLA-DR) fully human IgG4 antibody isolated by MorphoSys AG (from its HuCAL library of human antibodies), for the potential treatment of hematological malignancies. In December 2006, positive safety data from two phase I clinical trials were reported. Final phase I data were expected in mid-2007; however, no additional data have been released at the time of publication.